Infectious disease markets have never been more dynamic. The confluence of antimicrobial resistance (AMR), rapid vaccine innovation, emerging viral outbreaks, and shifting regulatory and payer environments means that life-science decision-makers need precise, timely, and disease-specific market intelligence. This article ranks leading market research firms that specialize—or have robust capabilities—in infectious diseases research, and explains why each provider matters for go/no-go development decisions, commercial strategy, licensing, and investment due diligence.
We assessed firms on five pragmatic dimensions that matter to healthcare executives and investors:
Therapeutic-area depth: demonstrable infectious-disease coverage and subject-matter expertise.
Data breadth and quality: access to real-world datasets, clinical trials intelligence, epidemiology and forecasting models.
Custom consulting and advisory: ability to deliver bespoke market access, pricing, and portfolio strategy.
Analytic sophistication: use of predictive modelling, AI/ML, and scenario planning for pipeline and market forecasts.
Reputation and commercial reach: track record with big pharma, biotech, and public-health agencies.
Below are top providers that consistently meet these requirements, with a lens on strategic value for product teams, commercial leaders, and investors.
IQVIA is a market leader in combining claims, electronic medical records, prescription and commercial datasets with advanced analytics—delivering end-to-end evidence generation from early R&D through post-launch optimization. IQVIA’s dedicated infectious diseases and vaccines practice offers trial design, real-world evidence (RWE), and forecasting capabilities that help sponsors size markets, optimize trial sites, and model uptake for vaccines and antimicrobials. Large pharma and investors rely on IQVIA when they need rigorous, cross-sectional datasets linked with commercial insights.
Clarivate’s Cortellis and related life sciences suites excel at pipeline intelligence, patent landscaping, and regulatory tracking—critical for mapping competitive dynamics in infectious diseases (e.g., antivirals, monoclonal antibodies, and vaccine platforms). Clarivate also curates disease-level datasets and real-world data offerings that accelerate due diligence and portfolio prioritization. Their specialized datasets (including curated COVID/virology collections) are particularly useful for teams needing rapid, evidence-based snapshots of research activity and approval risk.
GlobalData combines thematic market research, commercial forecasting, and industry-level analytics that help investors and corporate strategists quantify addressable markets and identify disruptive trends (e.g., microbiome therapeutics, AMR diagnostics). Their industry reports and expert commentary provide a practical balance of narrative insight and modeled forecasts—useful for screening investments and prioritizing indications. Many pharma teams pair GlobalData’s macro forecasts with a data partner for primary-care and payer analytics.
DelveInsight is a specialist life-sciences market research and consulting firm focused on in-depth disease landscapes, epidemiology, and pipeline analysis. They produce therapeutic-area reports that include clinical trial overviews, market forecasts, and payer access considerations—often at a disease-specific granularity that is useful for small-to-mid-sized biotechs and investors performing indication-level diligence. DelveInsight’s boutique model offers hands-on consulting and customized deliverables for infectious-disease programs.
Frost & Sullivan brings a growth-strategy orientation to healthcare research, coupling market forecasting with competitive benchmarking and go-to-market playbooks. In infectious diseases, their reports typically cover advanced therapeutics, diagnostics and health-system adoption barriers—insights that inform enterprise strategy, licensing negotiations, and long-range investment theses. Their advisory teams are well-suited for cross-sector initiatives (e.g., diagnostics + therapeutics + public health procurement).
BCC Research / MarketsandMarkets: good for focused market-sizing reports (diagnostics, vaccine delivery systems).
EvaluatePharma / Informa (Datamonitor/Pharmaprojects): strong for commercial forecasting and deal comparables.
Specialist consultancies and academic partnerships: for bespoke epidemiology modelling and pathogen-specific studies, partnering with university groups or niche consultancies can deliver high-precision insights.
Define the decision and timeline. Is this for a quick go/no-go, or a multi-year launch plan? Faster timelines typically favor large data vendors with off-the-shelf models (e.g., IQVIA, Clarivate).
Match evidence to stage. Early R&D needs pipeline & trial intelligence; commercial launch needs payer and prescriber segmentation. Align vendor capabilities to stage.
Ask for method transparency. Insist on reproducible assumptions: epidemiology sources, uptake curves, pricing scenarios, and how RWE cohorts were constructed.
Request a modular scope. Start with a tractable deliverable (e.g., 6-month market assessment) that can scale into multi-year subscriptions.
Validate with primary research. For novel mechanisms or narrow indications, combine secondary market reports with targeted KOL interviews and payer surveys.
Disease landscape and unmet-need dashboards (incidence, burden, standard of care).
Portfolio prioritization and head-to-head therapeutic comparisons.
Payer and HTA scenario mapping (reimbursement risk, evidence thresholds).
Commercial forecasts and pricing sensitivity analyses.
Clinical trial site identification and feasibility analysis (critical in outbreaks).
Investor-grade diligence packages with risk-adjusted NPV and comparable deals.
Negotiate pilot projects or single-report purchases before committing to enterprise licenses.
Clarify data refresh cadence and update fees for subscription products—infectious-disease landscapes evolve quickly.
Ask about custom data integrations (e.g., plugging vendor outputs into your internal dashboards or BI tools).
For investor diligence, request a condensed “board-ready” briefing deck and an analyst call to probe assumptions.
There is no single “best” vendor for every infectious-disease need. Large integrated data firms (IQVIA, Clarivate) excel when you need comprehensive, reproducible datasets and RWE at scale. Mid-sized and specialist firms (DelveInsight, GlobalData, Frost & Sullivan) provide disease-specific depth and strategic advisory services that are often more cost-efficient for focused programs. For high-stakes decisions—licensing, late-stage development, or major investment rounds—combine at least two providers (one data-centric and one consultancy-centric) and validate assumptions through primary research.